Medicine and Dentistry
Crohn's Disease
100%
Cost-Effectiveness Analysis
100%
Enzyme Linked Immunosorbent Assay
100%
Therapeutic Drug Monitoring
100%
Infliximab
100%
Clinician
66%
Health Care Cost
33%
Recurrence Risk
33%
Quality of Life
33%
Biological Product
33%
National Health Service
33%
Biological Marker
33%
Patient with Crohn's Disease
33%
Drug Megadose
33%
Decision Making
33%
Nursing and Health Professions
ELISA Kit
100%
Cost Effectiveness Analysis
100%
Crohn's Disease
100%
Infliximab
100%
Therapeutic Drug Monitoring
75%
Clinical Outcome
50%
Quality of Life
25%
Socialized Medicine
25%
Treatment Failure
25%
Remission
25%
Clinical Judgment
25%
Drug Megadose
25%
Biological Product
25%
Biological Marker
25%
Patient with Crohn's Disease
25%
Recurrence Risk
25%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
100%
Crohn's Disease
100%
Enzyme-Linked Immunosorbent Assay
100%
Therapeutic Drug Monitoring
75%
Recurrence Risk
25%
Biological Marker
25%
Remission
25%
Biological Product
25%